Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Combination of Liposomal CpG Oligodeoxynucleotide 2006 and Miltefosine Induces Strong Cell-Mediated Immunity during Experimental Visceral Leishmaniasis
Rahul Shivahare, Preeti Vishwakarma, N. Parmar, et al.
PLoS ONE (2014) Vol. 9, Iss. 4, pp. e94596-e94596
Open Access | Times Cited: 43

Showing 1-25 of 43 citing articles:

CpG Oligonucleotides as Vaccine Adjuvants
Neslihan Kayraklioglu, Begum Horuluoglu, Dennis M. Klinman
Methods in molecular biology (2020), pp. 51-85
Closed Access | Times Cited: 90
Antileishmanial Activity of Pyrazolopyridine Derivatives and Their Potential as an Adjunct Therapy with Miltefosine
Devireddy Anand, Pawan Kumar Yadav, Om Prakash Patel, et al.
Journal of Medicinal Chemistry (2017) Vol. 60, Iss. 3, pp. 1041-1059
Closed Access | Times Cited: 84
Nitroimidazo-oxazole compound DNDI-VL-2098: an orally effective preclinical drug candidate for the treatment of visceral leishmaniasis
Suman Gupta, Vanessa Yardley, Preeti Vishwakarma, et al.
Journal of Antimicrobial Chemotherapy (2014) Vol. 70, Iss. 2, pp. 518-527
Closed Access | Times Cited: 63
Systematic Review of Host-Mediated Activity of Miltefosine in Leishmaniasis through Immunomodulation
Semra Palić, Patrick A. Bhairosing, Jos H. Beijnen, et al.
Antimicrobial Agents and Chemotherapy (2019) Vol. 63, Iss. 7
Open Access | Times Cited: 47
Visceral leishmaniasis: An overview of vaccine adjuvants and their applications
Sneha Ratnapriya, Keerti Keerti, Amogh A. Sahasrabuddhe, et al.
Vaccine (2019) Vol. 37, Iss. 27, pp. 3505-3519
Closed Access | Times Cited: 46
Immune response and protective profile elicited by a multi-epitope chimeric protein derived from Leptospira interrogans
Luis G. V. Fernandes, Aline F. Teixeira, Antônio Francisco de Souza Filho, et al.
International Journal of Infectious Diseases (2017) Vol. 57, pp. 61-69
Open Access | Times Cited: 42
Mahanine exerts in vitro and in vivo antileishmanial activity by modulation of redox homeostasis
Saptarshi Roy, Devawati Dutta, Eswara Murali Satyavarapu, et al.
Scientific Reports (2017) Vol. 7, Iss. 1
Open Access | Times Cited: 41
Ammonium trichloro [1,2-ethanediolato-O,O′]-tellurate cures experimental visceral leishmaniasis by redox modulation of Leishmania donovani trypanothione reductase and inhibiting host integrin linked PI3K/Akt pathway
Preeti Vishwakarma, N. Parmar, Pragya Chandrakar, et al.
Cellular and Molecular Life Sciences (2017) Vol. 75, Iss. 3, pp. 563-588
Open Access | Times Cited: 35
Leishmania donovani Exploits Tollip, a Multitasking Protein, To Impair TLR/IL-1R Signaling for Its Survival in the Host
N. Parmar, Pragya Chandrakar, Preeti Vishwakarma, et al.
The Journal of Immunology (2018) Vol. 201, Iss. 3, pp. 957-970
Open Access | Times Cited: 35
Hamster, a close model for visceral leishmaniasis: Opportunities and challenges
Sheetal Saini, Ambak Kumar
Parasite Immunology (2020) Vol. 42, Iss. 10
Closed Access | Times Cited: 29
A Vaccine Based on the Receptor-Binding Domain of the Spike Protein Expressed in Glycoengineered Pichia pastoris Targeting SARS-CoV-2 Stimulates Neutralizing and Protective Antibody Responses
Bo Liu, Ying Yin, Yuxiao Liu, et al.
Engineering (2021) Vol. 13, pp. 107-115
Open Access | Times Cited: 25
Nanotechnology-aided diagnosis, treatment and prevention of leishmaniasis
Olga Kammona, Evgenia Tsanaktsidou
International Journal of Pharmaceutics (2021) Vol. 605, pp. 120761-120761
Closed Access | Times Cited: 24
Leishmania donovani Utilize Sialic Acids for Binding and Phagocytosis in the Macrophages through Selective Utilization of Siglecs and Impair the Innate Immune Arm
Saptarshi Roy, Chitra Mandal
PLoS neglected tropical diseases (2016) Vol. 10, Iss. 8, pp. e0004904-e0004904
Open Access | Times Cited: 30
A CpG-Ficoll Nanoparticle Adjuvant for Anthrax Protective Antigen Enhances Immunogenicity and Provides Single-Immunization Protection against Inhaled Anthrax in Monkeys
Melissa A. Kachura, Colin Hickle, Sariah Kell, et al.
The Journal of Immunology (2015) Vol. 196, Iss. 1, pp. 284-297
Open Access | Times Cited: 26
Carbonate Apatite Nanoparticles Act as Potent Vaccine Adjuvant Delivery Vehicles by Enhancing Cytokine Production Induced by Encapsulated Cytosine-Phosphate-Guanine Oligodeoxynucleotides
Hideki Takahashi, Kazuki Misato, Taiki Aoshi, et al.
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 26
CpG ODN D35 improves the response to abbreviated low-dose pentavalent antimonial treatment in non-human primate model of cutaneous leishmaniasis
Seth G. Thacker, Ian L. McWilliams, Béatrice Bonnet, et al.
PLoS neglected tropical diseases (2020) Vol. 14, Iss. 2, pp. e0008050-e0008050
Open Access | Times Cited: 21
Ex Vivo Host and Parasite Response to Antileishmanial Drugs and Immunomodulators
Laura Gonzalez‐Fajardo, Olga Lucía Fernández, Diane McMahon‐Pratt, et al.
PLoS neglected tropical diseases (2015) Vol. 9, Iss. 5, pp. e0003820-e0003820
Open Access | Times Cited: 23
Immunoprotective effect of lentinan in combination with miltefosine on Leishmania‐infected J‐774A.1 macrophages
Rahul Shivahare, Wahid Ali, Uma Shankar Singh, et al.
Parasite Immunology (2016) Vol. 38, Iss. 10, pp. 618-627
Closed Access | Times Cited: 21
In vivo experiments demonstrate the potent antileishmanial efficacy of repurposed suramin in visceral leishmaniasis
Supriya Khanra, Subir Kumar Juin, Junaid Jibran Jawed, et al.
PLoS neglected tropical diseases (2020) Vol. 14, Iss. 8, pp. e0008575-e0008575
Open Access | Times Cited: 19
Immucillins ImmA and ImmH Are Effective and Non-toxic in the Treatment of Experimental Visceral Leishmaniasis
Elisângela Oliveira de Freitas, Dirlei Nico, Marcus Vinícius Alves-Silva, et al.
PLoS neglected tropical diseases (2015) Vol. 9, Iss. 12, pp. e0004297-e0004297
Open Access | Times Cited: 20
Immunomodulatory nanoparticles ameliorate disease in the Leishmania (Viannia) panamensis mouse model
Alyssa Siefert, Allison Ehrlich, María Jesús Corral, et al.
Biomaterials (2016) Vol. 108, pp. 168-176
Open Access | Times Cited: 19
Differential Role of Leptin as an Immunomodulator in Controlling Visceral Leishmaniasis in Normal and Leptin-Deficient Mice
Radheshyam Maurya, Parna Bhattacharya, Nevien Ismail, et al.
American Journal of Tropical Medicine and Hygiene (2016) Vol. 95, Iss. 1, pp. 109-119
Open Access | Times Cited: 18
Withania somnifera chemotype NMITLI 101R significantly increases the efficacy of antileishmanial drugs by generating strong IFN-γ and IL-12 mediated immune responses in Leishmania donovani infected hamsters
Chandra Dev Pati Tripathi, Pramod Kumar Kushawaha, R. S. Sangwan, et al.
Phytomedicine (2016) Vol. 24, pp. 87-95
Closed Access | Times Cited: 15
Leptin augments protective immune responses in murine macrophages and enhances potential of miltefosine against experimental visceral leishmaniasis
Rahul Shivahare, Wahid Ali, Preeti Vishwakarma, et al.
Acta Tropica (2015) Vol. 150, pp. 35-41
Closed Access | Times Cited: 13
In vitro and in vivo therapeutic antileishmanial potential of ellagic acid against Leishmania donovani in murine model
Poonam Keshav, Deepak Goyal, Sukhbir Kaur
Medical Microbiology and Immunology (2022) Vol. 212, Iss. 1, pp. 35-51
Closed Access | Times Cited: 8
Page 1 - Next Page

Scroll to top